# Remedium Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/remedium-bio

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.remedium-bio.com
- Total disclosed funding: $12M
- Latest round: Series A (Aug 10, 2026)
- Investors on record: 9

## About

Founded in 2020, and based in Massachusetts, US, Remedium Bio Inc., operates as a gene therapy company that offers curative treatments for debilitating conditions. In August 2026, Remedium Bio Inc. raised USD 10 million in series A funding led by Lifespan Vision Ventures, with participation from Eli and Lilly Company and HKX Capital.


The company offers various gene therapy solutions in the fields of rheumatology, endocrinology, neurology, and immunology. The company offers a broad range of bio-pipelines of therapies for immune and age-related conditions.

The company plans to use the August 2026 funding to advance its lead programs, expand its platform, and prepare for first-in-human clinical studies.

## Funding rounds

- Series A, Aug 10, 2026, $10M — Eli Lilly and Company, HKX Capital, LifeSpan Vision Ventures
- Seed, Aug 15, 2022, $2.3M — MicroVentures, Longevity Tech Fund, Primo Medical Group, Apis Health Angels, Angel Star Ventures, Guindy Alumni Angels

## Investors

- MicroVentures — Seed
- Longevity Tech Fund (https://capitalatlas.ai/funds/longevity-tech-fund) — Seed
- Primo Medical Group — Seed
- Apis Health Angels — Seed
- Angel Star Ventures (https://capitalatlas.ai/funds/angel-star-ventures) — Seed
- Guindy Alumni Angels — Seed
- Eli Lilly and Company — Series A
- HKX Capital — Series A
- LifeSpan Vision Ventures (https://capitalatlas.ai/funds/lifespan-vision-ventures) — Series A